A novel bioluminescent bacterial biosensor for measurement of Ara-CTP and cytarabine potentiation by fludarabine in seven leukaemic cell lines

Leukemia Research

Volumn 37, Issue 6, 2013, Pages 690-696

  Anderson, Elizabeth ^a   Smith, M Ann ^b   Martin, Ashley ^c   Ruddock, Mark ^c   Lamont, John ^c   Alloush, Habib ^a   Conway, Myra ^a   Mehta, Priyanka ^d   Smith, J Graham ^e,f   Salisbury, Vyv ^a  

^a UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c Randox Laboratories Ltd   (United Kingdom)

^d UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF SURREY   (United Kingdom)

^f FRIMLEY PARK HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Acute myeloid leukaemia; Ara CTP; Biosensor

Indexed keywords

CYTARABINE; CYTARABINE TRIPHOSPHATE; FLUDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; BIOLUMINESCENT BACTERIAL BIOSENSOR; BIOSENSOR; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG RESPONSE; DRUG SENSITIVITY; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; BACTERIAL PROTEINS; BIOSENSING TECHNIQUES; CELL LINE, TUMOR; CYTARABINE; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA; LUMINESCENT MEASUREMENTS; LUMINESCENT PROTEINS; TREATMENT OUTCOME; VIDARABINE;

EID: 84877083246     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.02.012     Document Type: Article

References (42)

1. Robak T., Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009, 31(2):2349-2370.
2. Burnett A., Wetzler M., Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011, 29(5):487-494.
3. Moore J.O., George S.L., Dodge R.K., Amrein P.C., Powell B.L., Kolitz J.E., et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood 2005, 105:3420-3427.
4. Hu Z.B., Yang G.S., Li M., Miyamoto N., Minden M.D., McCulloch E.A. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals. Leukemia 1995, 9(5):789-798.
5. Carter B.Z., Kornblau S.M., Tsao T., Wang R.Y., Schober W.D., Milella M., et al. Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood 2003, 102:4179-4186.
6. Bezombes C., Laurent G., Jaffrezou J.P. Implication of raft microdomains in drug induced apoptosis. Curr Med Chem Anticancer Agents 2003, 3:263-270.
7. Mancini W.R. The role of deoxycytidine-metabolizing enzymes in the cytotoxicity induced by 3'-amino-2',3'-dideoxycytidine and cytosine arabinoside. Cancer Chemother Pharmacol 1992, 30(2):139-144.
8. Kufe D.W., Major P.P., Egan E.M., Beardsley G.P. Correlation of cytotoxicity with incorporation of Ara-C into DNA. J Biol Chem 1980, 255(19):8997-9900.
9. Galmarini C.M., Thomas X., Calvo F., Rousselot P., Rabilloud M., El Jaffari A., et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 2002, 117(4):860-868.
10. Koehl U., Hollatz G., Rohrbach E., Visschedyk K., Cinatl J., Kornhuber B., et al. Pharmacology of intracellular cytosine-arabinoside-5'-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes. Cancer Chemother Pharmacol 2007, 60(4):467-477.
11. Plunkett W., Hug V., Keating M.J., Chubb S. Quantitation of 1-β-d-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-d-arabinofuranosylcytosine therapy. Cancer Res 1980, 40:588-591.
12. Liliemark J.O., Plunkett W., Dixon D.O. Relationship of 1-β-d-arabinofuranosylcytosine in plasma to 1-β-d-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-β-d-arabinofuranosylcytosine. Cancer Res 1985, 45:5952-5957.
13. Plunkett W., Iacoboni S., Estey E., Danhauser L., Liliemark J.O., Keating M.J. Pharmacologically directed Ara-C therapy for refractory leukemia. Semin Oncol 1985, 12(Suppl. 3):20-30.
14. Iacoboni S.J., Plunkett W., Kantarjian H.M., Estey E., Keating M.J., McCredie K.B., et al. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 1986, 4:1079-1088.
15. Heinemann V., Estey E., Keating M.J., Plunkett W. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J Clin Oncol 1989, 7:622-628.
16. Cai J., Damaraju V.L., Groulx N., Mowles D., Peng Y., Robins M.J., et al. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res 2008, 68(7):2349-2357.
17. Song J.H., Kim S.H., Kweon S.H., Lee T.H., Kim H.J., Kim H.J., et al. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells. Int J Oncol 2009, 34(4):1165-1171.
18. Dumontet C., Bauchu E.C., Fabianowska K., Lepoivre M., Wyczechowska D., Bodin F., et al. Common resistance mechanisms to nucleoside analogues in variants of the human erythroleukemic line K562. Adv Exp Med Biol 1999, 457:571-577.
19. Schröder J.K., Kirch C., Flasshove M., Kalweit H., Seidelmann M., Hilger R., et al. Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. Leukemia 1996, 10(12):1919-1924.
20. Alloush H.M., Anderson E., Martin A.D., Ruddock M.W., Angell J.E., Hill P.J., et al. A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia. Clin Chem 2010, 56(12):1862-1870.
21. Xie C., Edwards H., Xu X., Zhou H., Buck S.A., Stout M.L., et al. Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res 2010, 16(22):5499-5510.
22. Gandhi V., Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 1988, 48(2):329-334.
23. Zhang C., Ao Z., Seth A., Schlossman S.F. A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. J Immunol 1996, 157:3980-3987.
24. Vercesi A., Bernardes C., Hoffmann M., Gadelha F., Docampo R. Digitonin permeabilisation does not affect mitochondrial function and allows the determination of the mitochondrial membrane potential of Trypanosoma cruzi in situ. J Biol Chem 1991, 266:14431-14434.
25. Ahlmann M., Lanvers C., Lümkemann K., Rössig C., Freund A., Baumann M., et al. Modulation of Ara-CTP levels by fludarabine and hydroxyurea in leukemic cells. Leukemia 2001, 15:69-73.
26. Crauste C., Lefebvre I., Hovaneissian M., Puy J.Y., Roy B., Peyrottes S., et al. Development of a sensitive and selective LC/MS/MS method for the simultaneous determination of intracellular 1-beta-d-arabinofuranosylcytosine triphosphate (araCTP), cytidine triphosphate (CTP) and deoxycytidine triphosphate (dCTP) in a human follicular lymphoma cell line. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877(14-15):1417-1425.
27. Muus P., Drenthe-Schonk A., Haanen C., Wessels H., Linssen P. In-vitro studies on phosphorylation and dephosphorylation of cytosine arabinoside in human leukemic cells. Leuk Res 1987, 11(4):319-325.
28. Estey E.H., Keating M.J., McCredie K.B., Freireich E.J., Plunkett W. Cellular Ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia 1990, 4(2):95-99.
29. Köhl U., Schwabe D., Montag E., Bauer S., Mieth B., Cinatl J., et al. Formation of cytosine arabinoside-5'-triphosphate in different cultured lymphoblastic leukaemic cells with reference to their drug sensitivity. Eur J Cancer 1995, 31A(2):209-214.
30. Ossenkoppele G.J., Wijermans P.W., Nauta J.J., Huijgens P.C., Langenhuijsen M.M. Low-dose cytarabine for acute myeloid leukaemia and myelodysplastic syndromes: in vivo and in vitro cytotoxicity. Eur J Cancer 1991, 27:842-845.
31. Löwenberg B., Pabst T., Vellenga E., van Putten W., Schouten H.C., Graux C., et al. Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine Dose for Acute Myeloid Leukemia. N Engl J Med 2011, 364:1027-1036.
32. Braess J., Pförtner J., Kern W., Hiddemann W., Schleyer E. Cytidine deaminase-the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells. Ann Hematol 1999, 78(11):514-520.
33. Nagahara Y., Tanaka M., Shinomiya T. Mechanism of mitochondrial 7A6 antigen exposure triggered by distinct apoptotic pathways: involvement of caspases. Cytometry A 2007, 71(4):232-241.
34. Xue L., Borutaite V., Tolkovsky A.M. Inhibition of mitochondrial permeability transition and release of cytochrome c by anti-apoptotic nucleoside analogues. Biochem Pharmacol 2002, 64(3):441-449.
35. Grazide S., Maestre N., Veldman R.J., Bezombes C., Maddens S., Levade T., et al. Ara-C- and daunorubicin-induced recruitment of Lyn in sphingomyelinase-enriched membrane rafts. FASEB J 2002, 16(12):1685-1687.
36. Lillemark J.O., Plunkett W. Regulation of 1-beta-d-arabinofuranosylcytosine 5'-triphosphate accumulation in human leukemia cells by deoxycytidine 5'-triphosphate. Cancer Res 1986, 46(3):1079-1083.
37. Shao J., Zhou B., Chu B., Yen Y. Ribonucleotide reductase inhibitors and future drug design. Curr Cancer Drug Targets 2006, 6(5):409-431.
38. Meuth M. The molecular basis of mutations induced by deoxyribonucleoside triphosphate pool imbalances in mammalian cells. Exp Cell Res 1989, 181(2):305-316.
39. Yamauchi T., Negoro E., Kishi S., Takagi K., Yoshida A., Urasaki Y., et al. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells. Biochem Pharmacol 2009, 77(12):1780-1786.
40. Plunkett W., Liliemark J.O., Adams T.M., Nowak B., Estey E., Kantarjian H., et al. Saturation of 1-β-d-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-β-d-arabinofuranosylcytosine therapy. Cancer Res 1987, 47(11):3005-3011.
41. Gandhi V., Kemena A., Keating M.J., Plunkett W. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 1992, 52(4):897-903.
42. Gandhi V., Plunkett W. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells. Cancer Chemother Pharmacol 1992, 31(1):11-17.